All Stories

  1. May Endocrine Therapy be Associated with Cognitive Impairment in Breast Cancer Patients?

    Article • Clinical Cancer Drugs, January 2019, Bentham Science Publishers

    Professor Guido Bocci, Riccardo Presciuttini

  2. Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World

    Article • Clinical Cancer Drugs, January 2018, Bentham Science Publishers

    Professor Guido Bocci

  3. Prevention of Capecitabine Toxicity Using a 5-FU Test Dose

    Article • Clinical Cancer Drugs, January 2018, Bentham Science Publishers

    Professor Guido Bocci

  4. Aggressive lymphomas of the elderly: the DEVEC metronomic chemotherapy schedule fits the unfit

    Article • British Journal of Haematology, November 2017, Wiley

    Professor Guido Bocci, MARIA COX

  5. Scholars and scientists in the history of the lymphatic system

    Article • Journal of Anatomy, June 2017, Wiley

    Professor Guido Bocci

  6. John Hunter and the origin of the term “angiogenesis”

    Article • Angiogenesis, February 2016, Springer Science + Business Media

    Professor Guido Bocci

  7. Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development

    Article • Future Oncology, February 2016, Future Medicine

    Professor Guido Bocci

  8. IL-8 and VEGFR-2 polymorphisms modulate long-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration

    Article • Pharmacogenomics, January 2016, Future Medicine

    Professor Guido Bocci, Prof. Michele Figus, Prof. Paolo Piaggi

  9. Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2

    Article • European Journal of Medicinal Chemistry, October 2015, Elsevier

    Professor Guido Bocci

  10. Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward

    Article • Angiogenesis, September 2015, Springer Science + Business Media

    Professor Guido Bocci

  11. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation

    Article • Endocrine, August 2015, Springer Science + Business Media

    Professor Guido Bocci

  12. Methods: for studying pharmacogenetic profiles of combination chemotherapeutic drugs

    Article • Expert Opinion on Drug Metabolism & Toxicology, June 2015, Informa Healthcare

    Professor Guido Bocci

  13. Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab

    Article • Pharmacogenomics, December 2014, Future Medicine

    Professor Guido Bocci, sabrina molinaro

  14. Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro

    Article • Surgery, November 2014, Elsevier

    Professor Guido Bocci

  15. Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients

    Article • Cancer, August 2014, Wiley

    Professor Guido Bocci

  16. CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo

    Article • Molecular and Cellular Endocrinology, August 2014, Elsevier

    Professor Guido Bocci

  17. The Preclinical Bases of the Rational Combination of Paclitaxel and Antiangiogenic Drugs

    Article • Clinical Cancer Drugs, May 2014, Bentham Science Publishers

    Professor Guido Bocci

  18. CLM3, a Multitarget Tyrosine Kinase Inhibitor With Antiangiogenic Properties, Is Active Against Primary Anaplastic Thyroid Cancer In Vitro and In Vivo

    Article • The Journal of Clinical Endocrinology & Metabolism, April 2014, Endocrine Society

    Professor Guido Bocci

  19. Structure-Based Optimization of Tyrosine Kinase Inhibitor CLM3 . Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies.

    Article • Journal of Medicinal Chemistry, February 2014, American Chemical Society (ACS)

    Professor Guido Bocci

  20. Pharmacokinetics and Pharmacogenetics of Metronomic Chemotherapy

    Article • January 2014, Springer Science + Business Media

    Professor Guido Bocci

  21. Breast Lymphomas Around Breast Implants

    Article • Annals of Surgery, January 2014, Wolters Kluwer Health

    Professor Guido Bocci

  22. Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1

    Article • The Journal of Clinical Endocrinology & Metabolism, September 2013, Endocrine Society

    Professor Guido Bocci

  23. Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections

    Article • International Journal of Antimicrobial Agents, September 2013, Elsevier

    Professor Guido Bocci

  24. Pharmacogenetic labyrinth of neovascular age-related macular degeneration therapy: how to escape and move forward?

    Article • Pharmacogenomics, August 2013, Future Medicine

    Professor Guido Bocci

  25. EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan

    Article • Targeted Oncology, July 2013, Springer Science + Business Media

    Professor Guido Bocci

  26. VEGF-Apolymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration

    Article • Pharmacogenomics, April 2013, Future Medicine

    Professor Guido Bocci, Prof. Michele Figus

  27. The pharmacological bases of the antiangiogenic activity of paclitaxel

    Article • Angiogenesis, February 2013, Springer Science + Business Media

    Professor Guido Bocci

  28. Feto-placental nitric oxide, asymmetric dimethylarginine and vascular endothelial growth factor (VEGF) levels and VEGF gene polymorphisms in severe preeclampsia

    Article • The Journal of Maternal-Fetal & Neonatal Medicine, October 2012, Taylor & Francis

    Professor Guido Bocci

  29. Population Pharmacokinetic Analysis of 5-FU and 5-FDHU in Colorectal Cancer Patients: Search for Biomarkers Associated with Gastro-Intestinal Toxicity

    Article • Current Topics in Medicinal Chemistry, October 2012, Bentham Science Publishers

    Professor Guido Bocci

  30. Metronomic Ceramide Analogs Inhibit Angiogenesis in Pancreatic Cancer through Up-regulation of Caveolin-1 and Thrombospondin-1 and Down-regulation of Cyclin D1

    Article • Neoplasia, September 2012, Elsevier

    Professor Guido Bocci

  31. Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration

    Article • Pharmacogenomics, July 2012, Future Medicine

    Professor Guido Bocci, Prof. Michele Figus

  32. EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis

    Article • Cancer and Metastasis Reviews, June 2012, Springer Science + Business Media

    Professor Guido Bocci

  33. The possible role of chemotherapy in antiangiogenic drug resistance

    Article • Medical Hypotheses, May 2012, Elsevier

    Professor Guido Bocci

  34. Cyclophosphamide-based metronomic chemotherapy: After 10 years of experience, where do we stand and where are we going?

    Article • Critical Reviews in Oncology/Hematology, April 2012, Elsevier

    Professor Guido Bocci

  35. CLM94, a Novel Cyclic Amide with Anti-VEGFR-2 and Antiangiogenic Properties, Is Active against Primary Anaplastic Thyroid Cancerin Vitroandin Vivo

    Article • The Journal of Clinical Endocrinology & Metabolism, April 2012, Endocrine Society

    Professor Guido Bocci, Dr Alessandro Antonelli

  36. Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers

    Article • Angiogenesis, March 2012, Springer Science + Business Media

    Professor Guido Bocci

  37. The rs2071559 AA VEGFR-2 Genotype Frequency Is Significantly Lower in Neovascular Age-Related Macular Degeneration Patients

    Article • The Scientific World JOURNAL, January 2012, Hindawi Publishing Corporation

    Professor Guido Bocci, Prof. Michele Figus

  38. Pharmacokinetic and Pharmacogenetic Predictive Markers of Irinotecan Activity and Toxicity

    Article • Current Drug Metabolism, December 2011, Bentham Science Publishers

    Professor Guido Bocci

  39. ALK-1–Negative Anaplastic Large Cell Lymphoma Associated With Breast Implants: A New Clinical Entity

    Article • Clinical Breast Cancer, October 2011, Elsevier

    Professor Guido Bocci

  40. Bevacizumab pharmacogenetics in tumor treatment: still looking for the right pieces of the puzzle

    Article • Pharmacogenomics, August 2011, Future Medicine

    Professor Guido Bocci

  41. Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells

    Article • Biochemical Pharmacology, June 2011, Elsevier

    Professor Guido Bocci

  42. First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study

    Article • Investigational New Drugs, April 2011, Springer Science + Business Media

    Professor Mario Giorgi, Professor Guido Bocci

  43. Irinotecan Synergistically Enhances the Antiproliferative and Proapoptotic Effects of Axitinib In Vitro and Improves Its Anticancer Activity In Vivo

    Article • Neoplasia, March 2011, Elsevier

    Professor Guido Bocci

  44. Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activityin Vitroandin Vivoin Papillary Dedifferentiated Thyroid Cancer

    Article • The Journal of Clinical Endocrinology & Metabolism, February 2011, Endocrine Society

    Professor Guido Bocci

  45. C11 Cytotoxic drugs

    Article • January 2011, Springer Science + Business Media

    Professor Guido Bocci

  46. Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activityin Vitroandin Vivoin Papillary Dedifferentiated Thyroid Cancer

    Article • Molecular Endocrinology, January 2011, Endocrine Society

    Professor Guido Bocci

  47. Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activityin Vitroandin Vivoin Papillary Dedifferentiated Thyroid Cancer

    Article • Endocrinology, January 2011, Endocrine Society

    Professor Guido Bocci

  48. Overexpression and Functional Relevance of Somatostatin Receptor-1, -2, and -5 in Endometrium and Endometriotic Lesions

    Article • The Journal of Clinical Endocrinology & Metabolism, December 2010, Endocrine Society

    Professor Guido Bocci

  49. Metronomic Chemotherapy for Metastatic Prostate Cancer

    Article • Drugs & Aging, September 2010, Springer Science + Business Media

    Professor Guido Bocci

  50. Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?

    Article • The EPMA Journal, July 2010, Springer Science + Business Media

    Professor Guido Bocci

  51. METRONOMIC CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH ADVANCED, CASTRATION-RESISTANT PROSTATE CANCER

    Article • Journal of the American Geriatrics Society, May 2010, Wiley

    Professor Guido Bocci

  52. A Rapid High-Performance Liquid Chromatography Method to Measure Linezolid and Daptomycin Concentrations in Human Plasma

    Article • Therapeutic Drug Monitoring, March 2010, Wolters Kluwer Health

    Professor Guido Bocci

  53. Pharmacogenetics of Angiogenesis

    Article • January 2010, Springer Science + Business Media

    Professor Guido Bocci

  54. The Biomodulatory Capacities of Low-Dose Metronomic Chemotherapy: Complex Modulation of the Tumor Microenvironment

    Article • January 2010, Springer Science + Business Media

    Professor Guido Bocci

  55. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer

    Article • European Journal of Pharmacology, October 2009, Elsevier

    Professor Guido Bocci

  56. Discordant somatic and germlineVEGF-Agenotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis

    Article • Pharmacogenomics, August 2009, Future Medicine

    Professor Guido Bocci

  57. Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction

    Article • British Journal of Clinical Pharmacology, January 2009, Wiley

    Professor Guido Bocci

  58. Pharmacogenetics of Antiangiogenic Therapy

    Article • January 2008, Springer Science + Business Media

    Professor Guido Bocci

  59. Markers of Cell Proliferation, Apoptosis, and Angiogenesis in Thyroid Adenomas: A Comparative Immunohistochemical and Genetic Investigation of Functioning and Nonfunctioning Nodules

    Article • Thyroid, March 2007, Mary Ann Liebert Inc

    Professor Guido Bocci

  60. Drug distribution in tumors: Mechanisms, role in drug resistance, and methods for modification

    Article • Current Oncology Reports, January 2007, Springer Science + Business Media

    Professor Guido Bocci

  61. Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy

    Article • Pharmacogenomics, January 2007, Future Medicine

    Professor Guido Bocci

  62. Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients

    Article • Pharmacogenetics and Genomics, November 2006, Wolters Kluwer Health

    Professor Guido Bocci

  63. In vitro and in vivo antitumour effects of novel, orally active bile acid-conjugated platinum complexes on rat hepatoma

    Article • European Journal of Pharmacology, November 2006, Elsevier

    Professor Guido Bocci

  64. Clinical Pharmacokinetics of Irinotecan-Based Chemotherapy in Colorectal Cancer Patients

    Article • Current Clinical Pharmacology, September 2006, Bentham Science Publishers

    Professor Guido Bocci

  65. Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation

    Article • Cancer Chemotherapy and Pharmacology, May 2006, Springer Science + Business Media

    Professor Guido Bocci

  66. Microvessel Density in Human Normal and Neoplastic Parathyroids

    Article • Endocrine Pathology, January 2006, Springer Science + Business Media

    Professor Guido Bocci

  67. Cellular and Molecular Surrogate Markers to Monitor Targeted and Non- Targeted Antiangiogenic Drug Activity and Determine Optimal Biologic Dose

    Article • Current Cancer Drug Targets, November 2005, Bentham Science Publishers

    Professor Guido Bocci

  68. Improved Analysis of 5-Fluorouracil and 5,6-Dihydro-5-Fluorouracil by HPLC With Diode Array Detection for Determination of Cellular Dihydropyrimidine Dehydrogenase Activity and Pharmacokinetic Profiling

    Article • Therapeutic Drug Monitoring, June 2005, Wolters Kluwer Health

    Professor Guido Bocci

  69. 5-Fluorouracil catabolism to 5-fluoro-5,6-dihydrouracil is reduced by acute liver impairment in mice

    Article • Toxicology and Applied Pharmacology, March 2005, Elsevier

    Professor Guido Bocci

  70. Cytotoxic drugs

    Article • January 2005, Springer Science + Business Media

    Professor Guido Bocci

  71. Importance of Preclinical Investigations of the Integration of Capecitabine into Polychemotherapy Regimens

    Article • Clinical Colorectal Cancer, January 2005, Elsevier

    Professor Guido Bocci

  72. Angiogenesis and VEGF expression in pre-invasive lesions of the human breast

    Article • The Journal of Pathology, September 2004, Wiley

    Professor Guido Bocci

  73. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine

    Article • European Journal of Pharmacology, September 2004, Elsevier

    Professor Guido Bocci

  74. Biologic Basis of Ovarian Metastasis of Colorectal Cancer

    Article • Clinical Colorectal Cancer, February 2004, Elsevier

    Professor Guido Bocci

  75. Definition of the microvascular pattern of the normal human adult mammary gland

    Article • Journal of Anatomy, December 2003, Wiley

    Professor Guido Bocci

  76. Three-dimensional in vitro culture of endometrial explants mimics the early stages of endometriosis

    Article • Fertility and Sterility, November 2003, Elsevier

    Professor Guido Bocci

  77. Selective anti-endothelial effects of protracted low-dose BAL-9504, a novel geranylgeranyl-transferase inhibitor

    Article • European Journal of Pharmacology, September 2003, Elsevier

    Professor Guido Bocci

  78. Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients

    Article • British Journal of Clinical Pharmacology, May 2002, Wiley

    Professor Guido Bocci

  79. The effect of osteogenic growth peptide (OGP) on proliferation and adhesion of HEMC-1 human endothelial cells

    Article • Pharmacological Research, January 2002, Elsevier

    Professor Guido Bocci

  80. 5-Fluorouracil Administered as a 48-Hour Chronomodulated Infusion in Combination with Leucovorin and Cisplatin: A Randomized Phase II Study in Metastatic Colorectal Cancer

    Article • Oncology, January 2001, Karger Publishers

    Professor Guido Bocci

  81. Variable Correlation Between 6-Mercaptopurine Metabolites in Erythrocytes and Hematologic Toxicity: Implications for Drug Monitoring in Children With Acute Lymphoblastic Leukemia

    Article • Therapeutic Drug Monitoring, August 2000, Wolters Kluwer Health

    Professor Guido Bocci

  82. An Improved HPLC Method for Therapeutic Drug Monitoring of Daunorubicin, Idarubicin, Doxorubicin, Epirubicin, and Their 13-Dihydro Metabolites in Human Plasma

    Article • Therapeutic Drug Monitoring, June 1999, Wolters Kluwer Health

    Professor Guido Bocci

  83. Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo

    Article • Cancer Chemotherapy and Pharmacology, March 1999, Springer Science + Business Media

    Professor Guido Bocci

  84. Metabolism of 6-mercaptopurine in the erythrocytes, liver, and kidney of rats during multiple-dose regimens

    Article • Cancer Chemotherapy and Pharmacology, February 1999, Springer Science + Business Media

    Professor Guido Bocci

  85. The Heparan Sulfate Suleparoide Inhibits Rat Corneal Angiogenesis and in vitro Neovascularization

    Article • Experimental Eye Research, August 1998, Elsevier

    Professor Guido Bocci

  86. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate

    Article • Cancer Chemotherapy and Pharmacology, March 1996, Springer Science + Business Media

    Professor Guido Bocci